title: Interaction of radiation therapy with molecular targeted agents.
abstract: The development of molecular targeted therapeutics in oncology builds on many years of scientific investigation into the cellular mechanics of malignant transformation and progression. The past two decades have brought an accelerating pace to the clinical investigation of new molecular targeted agents, particularly in the setting of metastatic disease. The integration of molecular targeted agents into phase III clinical trial design has lagged in the curative treatment setting, particularly in combination with established therapeutic modalities such as radiation. In this review, we discuss the interaction of radiation and molecular targeted therapeutics. The dynamics of cellular and tumor response to radiation offer unique opportunities for beneficial interplay with molecular targeted agents that may go unrecognized with conventional screening and monotherapy clinical testing of novel agents. By using epidermal growth factor receptor (EGFR) as a primary example, we discuss recent clinical studies that illustrate the potential synergy of molecular targeted agents with radiation and highlight the clinical value of such interactions. For various molecular targeted agents, their greatest clinical impact may rest in combination with radiation, and efforts to facilitate systematic investigation of this approach appear highly warranted.
authors.affiliation: All authors: University of Wisconsin School of Medicine and Public Health, Madison, WI.
authors.forename: Zachary S
authors.initials: ZS
authors.lastname: Morris
authors.affiliation: All authors: University of Wisconsin School of Medicine and Public Health, Madison, WI. harari@humonc.wisc.edu.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Harari
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D000970:Antineoplastic Agents
references.citation: J Clin Oncol. 2012 Nov 10;30(32):3953-9
references.pmid: 23045594
references.citation: Lancet Oncol. 2010 Jan;11(1):21-8
references.pmid: 19897418
references.citation: J Clin Oncol. 2013 May 20;31(15):1904-11
references.pmid: 23589547
references.citation: Clin Cancer Res. 2000 Jun;6(6):2166-74
references.pmid: 10873065
references.citation: J Natl Compr Canc Netw. 2012 Dec 1;10(12):1514-20
references.pmid: 23221789
references.citation: Lung Cancer. 2011 May;72(2):199-204
references.pmid: 20828860
references.citation: J Clin Oncol. 2014 Sep 20;32(27):2940-50
references.pmid: 25154822
references.citation: Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):998-1004
references.pmid: 19560883
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544
references.citation: Drug Resist Updat. 2012 Jun;15(3):173-82
references.pmid: 22561672
references.citation: Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):234-40
references.pmid: 23523324
references.citation: Cancer Res. 1999 Apr 15;59(8):1935-40
references.pmid: 10213503
references.citation: Ann Oncol. 2008 Jun;19(6):1110-6
references.pmid: 18344537
references.citation: Lancet Oncol. 2012 Feb;13(2):172-80
references.pmid: 22178121
references.citation: Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e609-15
references.pmid: 22208976
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1179-84
references.pmid: 22342094
references.citation: Proc Natl Acad Sci U S A. 1983 Mar;80(5):1337-41
references.pmid: 6298788
references.citation: J Clin Oncol. 2010 Jan 1;28(1):43-8
references.pmid: 19901100
references.citation: Nat Rev Drug Discov. 2011 Jun;10(6):417-27
references.pmid: 21629292
references.citation: J Cell Mol Med. 2011 Dec;15(12):2735-44
references.pmid: 21362133
references.citation: Cancer Treat Rev. 2012 Oct;38(6):626-40
references.pmid: 22196919
references.citation: Nat Clin Pract Oncol. 2007 Mar;4(3):172-80
references.pmid: 17327857
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1145-50
references.pmid: 528263
references.citation: J Clin Oncol. 2013 May 1;31(13):e220-2
references.pmid: 23530102
references.citation: Ann Oncol. 2011 Oct;22(10):2304-9
references.pmid: 21330337
references.citation: Oncol Rep. 2012 May;27(5):1303-11
references.pmid: 22323095
references.citation: N Engl J Med. 1982 Mar 4;306(9):517-22
references.pmid: 6173751
references.citation: Semin Radiat Oncol. 2013 Jan;23(1):31-7
references.pmid: 23207045
references.citation: Mol Interv. 2010 Dec;10(6):341-53
references.pmid: 21263160
references.citation: Clin Adv Hematol Oncol. 2012 Jul;10(7):430-7
references.pmid: 22895283
references.citation: Cancer. 2010 Aug 1;116(15):3537-48
references.pmid: 20564106
references.citation: N Engl J Med. 2007 Nov 15;357(20):2040-8
references.pmid: 18003960
references.citation: Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):476-82
references.pmid: 20598452
references.citation: Clin Cancer Res. 2010 Nov 15;16(22):5573-80
references.pmid: 20921209
references.citation: J Clin Oncol. 2009 Sep 1;27(25):4096-102
references.pmid: 19636002
references.citation: J Natl Cancer Inst. 2013 Feb 20;105(4):256-65
references.pmid: 23291374
references.citation: Cancer. 2012 Oct 15;118(20):5008-14
references.pmid: 22415650
references.citation: Mol Cancer Res. 2009 Jul;7(7):1000-12
references.pmid: 19584260
references.citation: J Clin Oncol. 2001 Jul 1;19(13):3234-43
references.pmid: 11432891
references.citation: Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e447-54
references.pmid: 22819210
references.citation: J Clin Oncol. 2012 May 10;30(14):1620-7
references.pmid: 22473163
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):995-1001
references.pmid: 28333021
references.citation: Cancer Biother Radiopharm. 1999 Dec;14(6):451-63
references.pmid: 10850332